Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Histologically confirmed locally advanced or stage IV NSCLC~* Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2~* Tumor tissue sections must be available for biomarker evaluation~Exclusion Criteria:~* Untreated or active/progressing Central Nervous system (CNS) metastases~* Active, known or suspected autoimmune disease~* Known history of testing positive for HIV or AIDS~* Active or chronic infection of hepatitis B virus or hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A Nivolumab (Type: EXPERIMENTAL): Opdivo specified dose on specified days
- Group A Nivolumab + SOC maintenance therapy (Type: EXPERIMENTAL): Opdivo/Bevacizumab specified dose on specified days~Opdivo/Pemetrexed specified dose on specified days
- Group A SOC maintenance therapy (Type: ACTIVE_COMPARATOR): Bevacizumab specified dose on specified days~Pemetrexed specified dose on specified days
- Group B Nivolumab (Type: EXPERIMENTAL): Opdivo specified dose on specified days
- Group B Best supportive care (Type: OTHER): Therapy directed against specific symptoms of disease, i.e., palliative radiation or palliative surgery
- Group C Investigator's choice chemotherapy (Type: ACTIVE_COMPARATOR): Carboplatin/nab-paclitaxel specified dose on specified days~Carboplatin/paclitaxel specified dose on specified days~Carboplatin/pemetrexed specified dose on specified days~Carboplatin/docetaxel specified dose on specified days~Carboplatin/gemcitabine specified dose on specified days~Paclitaxel specified dose on specified days~Docetaxel specified dose on specified days~Gemcitabine specified dose on specified days~Pemetrexed specified dose on specified days
- Group C Nivolumb (Type: EXPERIMENTAL): Opdivo specified dose on specified days
- Group D Erlotinib (Type: ACTIVE_COMPARATOR): Erlotinib specified dose on specified days
- Group D Nivolumab + Erlotinib (Type: EXPERIMENTAL): Opdivo/Erlotnib specified dose on specified days
- Group E Nivolumab + Crizotinib (Type: EXPERIMENTAL): Opdivo/Crizotinib specified dose on specified days

Based on this trial design, predict the completion outcome and termination type (if applicable).